智通财经APP讯，福元医药(601089.SH)发布股价异动公告称，公司关注到近期市场对创新药业务关注 度较高。2025年4月9日，公司披露了《北京福元医药股份有限公司关于获得药物临床试验批准通知书的 公告》，公司1类创新药FY101注射液获得药物临床试验批准通知书，截至公告披露日，该项目尚处于I 期临床试验阶段，试验能否成功还存在重大不确定性。除前述信息外，公司目前未发现其他对公司股票 交易价格可能产生重大影响的媒体报告或市场传闻，不涉及其他市场热点概念事项。 ...

证券代码：601089 证券简称：福元医药 公告编号：临2025-055 北京福元医药股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 北京福元医药股份有限公司（以下简称"公司"或"本公司"）股票于 2025 年 7 月 31 日、8 月 1 日、8 月 4 日连续三个交易日收盘价格涨幅偏离值累计达到 20%， 根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 经公司自查，并向公司控股股东及实际控制人书面发函询证，截至本公告披 露日，除公司已披露事项外，本公司及控股股东、实际控制人不存在应披露而未披 露的重大事项。 一、股票交易异常波动的具体情况 2025 年 7 月 31 日至 8 月 4 日，公司股票连续三个交易日收盘价格涨幅偏离值累 计达到 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动 情形。 （一）生产经营情况 经向公司管理层核实确认，公司及子公司的生产经营活动一切正常，内外部环境未 发生重大变化，不存在应披露而未披露 ...

Core Viewpoint - The company has observed increased market attention on its innovative drug business, particularly following the announcement of receiving clinical trial approval for its first-class innovative drug FY101 injection [1] Group 1: Company Developments - The company disclosed that it received a drug clinical trial approval notice for FY101 injection on April 9, 2025, under announcement number 临2025-024 [1] - As of the date of the announcement, the FY101 project is still in the Phase I clinical trial stage, and there remains significant uncertainty regarding the success of the trial [1] Group 2: Market Context - The company has not identified any other media reports or market rumors that could significantly impact its stock trading price, indicating a stable market perception aside from the focus on its innovative drug [1]

Core Viewpoint - Fuyuan Pharmaceutical (601089) has experienced a significant stock price fluctuation, with a cumulative deviation of 20% over three consecutive trading days, attributed to increased market interest in its innovative drug business [1] Company Summary - The company has received a clinical trial approval notice for its Class 1 innovative drug, FY101 injection, which is currently in the Phase I clinical trial stage [1] - There remains significant uncertainty regarding the success of the ongoing clinical trials for FY101 [1]

Core Viewpoint - The stock of Fuyuan Pharmaceutical has experienced an abnormal fluctuation, with a cumulative increase of 20% over three consecutive trading days, prompting the company to clarify its operational status and market conditions [1] Company Operations - The company and its subsidiaries are operating normally, with no significant changes in the internal or external environment [1] - There are no undisclosed major issues that require disclosure [1] Market Focus - The market has shown heightened interest in the company's innovative drug business [1] - The company's first-class innovative drug, FY101 injection, has received approval for clinical trial notification and is currently in the Phase I clinical trial stage [1] - There remains significant uncertainty regarding the success of the clinical trial [1]

福元医药股票交易异常波动的公告，公司关注到近期市场对创新药业务关注度较高。2025年4月9日，公 司披露了《北京福元医药股份有限公司关于获得药物临床试验批准通知书的公告》（公告编号：临 2025-024），公司1类创新药FY101注射液获得药物临床试验批准通知书，截至本公告披露日，该项目 尚处于I期临床试验阶段，试验能否成功还存在重大不确定性。除前述信息外，公司目前未发现其他对 公司股票交易价格可能产生重大影响的媒体报告或市场传闻，不涉及其他市场热点概念事项。 ...

Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]

天眼查商业履历信息显示，北京福元医药股份有限公司，成立于1999年，位于北京市，是一家以从事医 药制造业为主的企业。企业注册资本48000万人民币，实缴资本48000万人民币。公司法定代表人为黄 河。 通过天眼查大数据分析，北京福元医药股份有限公司共对外投资了3家企业，参与招投标项目5000次， 知识产权方面有商标信息214条，专利信息141条，此外企业还拥有行政许可148个。 来源：金融界 金融界消息 截至2025年8月4日收盘，福元医药（601089）报收于29.19元，上涨9.98%，换手率6.38%， 成交量30.64万手，成交金额8.85亿元。 资金流向方面，今日主力资金净流入9796.96万元，占比成交额11.07%。其中，超大单净流入1.48亿 元、占成交额16.69%，大单净流出4969.80万元、占成交额5.62%，中单净流出流出5398.87万元、占成 交额6.1%，小单净流出4398.09万元、占成交额4.97%。 福元医药最新一期业绩显示，截至2025一季报，公司营业总收入8.30亿元、同比增长3.46%，归属净利 润1.31亿元，同比减少1.47%，扣非净利润1.22亿元，同比减少1 ...

福元医药再度涨停，5个交易日内录得3个涨停，累计涨幅为40.20%，累计换手率为17.57%。截至9:31， 该股今日成交量411.56万股，成交金额1.18亿元，换手率0.86%。最新A股总市值达140.11亿元。 4月30日公司发布的一季报数据显示，一季度公司共实现营业总收入8.30亿元，同比增长3.46%，实现净 利润1.31亿元，同比下降1.47%。（数据宝） 近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.08.01 | 9.99 | 2.11 | 10078.80 | | 2025.07.31 | 0.79 | 5.23 | 2272.62 | | 2025.07.30 | 4.54 | 5.68 | -1200.90 | | 2025.07.29 | 9.99 | 3.69 | 9650.80 | | 2025.07.28 | 0.10 | 1.51 | -304.22 | | 2025.07.25 | -2.48 | 2.31 | -2584.41 | | 2025.07.24 | ...

Market Overview - As of August 1, the Shanghai Composite Index closed at 3559.95 points, with a decline of 0.37%. The Shenzhen Component Index closed at 10991.32 points, down 0.17%, and the ChiNext Index closed at 2322.63 points, decreasing by 0.24% [1]. Trading Volume Analysis - A total of 1503 stocks saw an increase in average transaction volume, with 31 stocks experiencing a rise of over 50%. Conversely, 3051 stocks reported a decrease in average transaction volume [1]. - Notable stocks with significant increases in average transaction volume include Kecuan Technology, Shenghui Integration, and Zhengzhong Design [1]. Active Stocks by Transaction Volume - The stocks with the highest increase in average transaction volume on August 1 include: - Kecuan Technology: 9.99% increase, average transaction volume of 1014 shares, up 193.10% [3]. - Shenghui Integration: 10.00% increase, average transaction volume of 672 shares, up 191.70% [3]. - Zhengzhong Design: 10.00% increase, average transaction volume of 2134 shares, up 168.74% [3]. Active Stocks by Transaction Count - The stocks with the highest increase in transaction count on August 1 include: - Anzheng Fashion: -1.69% change, with 68,433 transactions, up 1618.56% [2]. - Yingweike: 2.04% change, with 218,079 transactions, up 1082.38% [2]. - Zhongjiabo Chuang: -3.90% change, with 48,487 transactions, up 656.19% [2]. Stocks with Significant Increases in Both Volume and Count - Kecuan Technology stands out with a 9.99% increase, an average transaction volume of 1014 shares (up 193.10%), and a transaction count of 16,921 (up 126.52%) [4]. - Other notable stocks include: - Jiejia Weichuang: 20.00% increase, average transaction volume of 838 shares (up 130.45%), and 57,709 transactions (up 121.19%) [4]. - Riyi Electronics: 10.01% increase, average transaction volume of 846 shares (up 113.00%), and 25,112 transactions (up 161.72%) [4].